Table 1 Characteristics and comparisons of the participants’ characteristics separated into three groups according to the type of anti-dementia drug used (n = 120)
From: Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
No treatment (n = 36) | CEIs (n = 43) | Memantine (n = 41) | P-value* | ||||
|---|---|---|---|---|---|---|---|
Overall | No treatment versus CEIs | No treatment versus memantine | CEIs versus memantine | ||||
Age, mean ± SD (years) | 81.3 ± 5.5 | 81.0 ± 6.6 | 83.4 ± 6.3 | 0.189 | - | - | - |
Female gender, n (%) | 22 (61.1) | 30 (69.8) | 25 (61.0) | 0.633 | - | - | - |
BMI, mean ± SD (kg/m2) | 26.9 ± 4.4 | 26.2 ± 4.9 | 26.1 ± 4.5 | 0.763 | - | - | - |
Number of drugs daily taken, mean ± SD | 6.2 ± 3.2 | 5.2 ± 3.3 | 6.0 ± 3.1 | 0.267 | - | - | - |
Use psychoactive drugs†, n (%) | 17 (47.2) | 16 (37.2) | 12 (29.3) | 0.348 | |||
MMSE score‡ (/30 points), mean ± SD | 20.8 ± 5.7 | 19.8 ± 4.6 | 14.7 ± 4.3 | <0.001 | 0.169 | <0.001 | <0.001 |
Time between visits, mean ± SD (days) | 232.9 ± 103.7 | 220.0 ± 67.5 | 186.7 ± 96.2 | 0.062 | - | - | - |
Walking speed (cm/s), mean ± SD | 68.3 ± 21.3 | 62.4 ± 21.3 | 60.9 ± 22.8 | 0.466 | - | - | - |
CoV of stride time (%), mean ± SD | |||||||
Before treatment | 4.8 ± 2.2 | 4.9 ± 2.8 | 6.1 ± 5.0 | 0.699 | - | - | - |
After treatment | 5.4 ± 5.7 | 5.8 ± 4.2 | 4.2 ± 2.4 | 0.035 | 0.084 | 0.647 | 0.010 |